Submissions from 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Stephen Xu, Sean T Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, and Xenofon Baraliakos
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data., Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip Mease, and Mark Lebwohl
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial., Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Laura C Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, Lyrica X H Liu, David Collier, and Dafna D Gladman
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study., Bruce Kirkham, Peter Nash, Delia Reina, Sandra Navarra, Erhard Quebe-Fehling, Corine Gaillez, Carlos Sastre, and Philip Mease
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials., Iain B McInnes, Andrew J K Ostor, Philip Mease, William Tillett, Xenofon Baraliakos, Kurt de Vlam, Louis Bessette, Ralph Lippe, Anna Maniccia, Dai Feng, Tianming Gao, Patrick Zueger, Christopher Saffore, Koji Kato, In-Ho Song, and Atul Deodhar
Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy., Philip Mease
Effectiveness of 6-Month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Taylor Blachley, Blessing Dube, Robert R McLean, Nina Kim, Peter Hur, and Alexis Ogdie
Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Soumya D Chakravarty, Robert R McLean, Taylor Blachley, Toana Kawashima, Iris Lin, Arthur Kavanaugh, and Alexis Ogdie
Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review., Philip Mease and Atul Deodhar
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis., Philip Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, and Subhashis Banerjee
Potential Impact of Sex and Body Mass Index on Response to Therapy in Psoriatic Arthritis: Post-hoc Analysis of Results From the SEAM-PsA Trial., Philip Mease, Dafna D Gladman, Joseph F Merola, Atul Deodhar, Alexis Ogdie, David H Collier, Lyrica Liu, and Arthur Kavanaugh
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE., Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, and Laure Gossec
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Alexis Ogdie, Soumya D Chakravarty, Natalie J Shiff, Iris Lin, Robert R McLean, Wendi Malley, Rebecca L Spitzer, Arthur Kavanaugh, and Joseph F Merola
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials., Philip Mease, Arthur Kavanaugh, Dafna Gladman, Oliver FitzGerald, Enrique R Soriano, Peter Nash, Dai Feng, Apinya Lertratanakul, Kevin Douglas, Ralph Lippe, and Laure Gossec
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase 3 Results in DMARD-Naive Patients With Psoriatic Arthritis., Philip Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F Wells, Martin Bergman, Dafna D Gladman, Sven Richter, Lichen Teng, Shauna Jardon, and Josef S Smolen
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial., Philip Mease, Herbert Kellner, Akimichi Morita, Alan J Kivitz, Stella Aslanyan, Steven J Padula, Andrew S Topp, Ann Eldred, Frank Behrens, and Kim A Papp
Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis., Philip Mease, Iain B McInnes, Lai-Shan Tam, Raji Rajalingam, Steve Peterson, Fareen Hassan, Soumya D Chakravarty, Christine Contré, Alison Armstrong, Wolf-Henning Boehncke, and Christopher Ritchlin
Best practice and research advances in many aspects of rheumatology., Philip Mease and Janet Pope
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis., Philip Mease, Désirée van der Heijde, Bruce Kirkham, Georg Schett, Ana-Maria Orbai, Christopher Ritchlin, Joseph F Merola, Luminita Pricop, David A James, Xuan Zhu, and Gregory Ligozio
COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination., Philip Mease, Kevin Winthrop, Wendy Olsder, and Jeffrey R Curtis
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database., Philip Mease, Pamela Young, David Gruben, Lara Fallon, Rebecca Germino, and Arthur Kavanaugh
Instrument selection for the ASAS core outcome set for axial spondyloarthritis., Victoria Navarro-Compán, Anne Boel, Annelies Boonen, Philip Mease, Maxime Dougados, Uta Kiltz, Robert B M Landewé, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, and Désirée van der Heijde
Prospective Cohort Study of Psoriatic Arthritis Risk in Patients With Psoriasis in a Real-World Psoriasis Registry., Alexis Ogdie, Ryan W Harrison, Robert R McLean, Tin-Chi Lin, Mark Lebwohl, Bruce E Strober, Joe Zhuo, Vardhaman Patel, and Philip J Mease
Challenges in the Diagnosis and Assessment of Psoriatic Arthritis., Alexis Ogdie, Christine A Lindsay, Philip Mease, Kristina Callis Duffin, Cheryl F Rosen, and Stefan Siebert
Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies., Ana-Maria Orbai, Philip J Mease, Philip S Helliwell, Oliver FitzGerald, Dona L Fleishaker, Rajiv Mundayat, and Pamela Young
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies., Christopher T Ritchlin, Philip Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes, and Atul Deodhar
Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases., Stefan Schreiber, Luis Puig, João Gonçalves, Philip Mease, Remo Panaccione, and Paul Emery
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting., Carmel Stober, Iain B McInnes, Soumya Raychaudhuri, Philip Mease, Stephen R Pennington, Jose U Scher, Vinod Chandran, April W Armstrong, Maarten de Wit, Alberto Cauli, Deepak R Jadon, Thorvardur J Löve, Alexis Ogdie, Denis O'Sullivan, Leonieke J J van Mens, Christopher T Ritchlin, and Oliver FitzGerald
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis., William Tillett, Laura C Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems, and Philip Mease
Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects., James C Waddington, Orla Coleman, Philip Mease, Vinod Chandran, Denis O'Sullivan, Oliver FitzGerald, and Stephen R Pennington
Submissions from 2021
Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative., Anna Antony, Richard Holland, Maria-Antonietta D'Agostino, Walter P Maksymowych, Heidi Bertheussen, Lori Schick, Niti Goel, Alexis Ogdie, Ana-Maria Orbai, P Højgaard, Laura C Coates, Vibeke Strand, Dafna D Gladman, Robin Christensen, Ying Ying Leung, Philip Mease, and William Tillett
Domains to be considered for the core outcome set of axial spondyloarthritis: results from a 3-round Delphi survey., Anne Boel, Victoria Navarro-Compán, Annelies Boonen, Philip Mease, Uta Kiltz, Maxime Dougados, Robert Landewé, and Désirée van der Heijde
Pustular Psoriasis and Associated Musculoskeletal Disorders., Kristina Callis Duffin, Hervé Bachelez, Philip J Mease, Cheryl Rosen, Amit Garg, Eric Zudak, Ori Elkayam, Joseph Merola, Jeffrey Chau, Mitsumasa Kishimoto, Victoria Furer, and Philip S Helliwell
Withdrawing Ixekizumab in Patients with Psoriatic Arthritis who Achieved Minimal Disease Activity: Results from a Randomized, Double-Blind Withdrawal Study., Laura C Coates, Sreekumar G Pillai, Hasan Tahir, Ivo Valter, Vinod Chandran, Hideto Kameda, Masato Okada, Lisa Kerr, Denise Alves, So Young Park, David H Adams, Gaia Gallo, Matthew M Hufford, Maja Hojnik, Philip Mease, Arthur Kavanaugh, and SPIRIT-P3 Study Group
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results., Atul A Deodhar, Philip Mease, Proton Rahman, Victoria Navarro-Compán, Vibeke Strand, Theresa Hunter, Rebecca Bolce, Luis Leon, Steve Lauzon, and Helena Marzo-Ortega
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks., Atul Deodhar, Philip Mease, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Steven Lauzon, Ann Leung, and Victoria Navarro-Compán
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib., Kurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, Joseph C Cappelleri, Roy Fleischmann, Peter C Taylor, Valderilio Azevedo, Lara Fallon, John Woolcott, and Philip J Mease
Pustular Psoriasis and Associated Musculoskeletal Disorders., Kristina Callis Duffin, Hervé Bachelez, Philip J Mease, Cheryl Rosen, Amit Garg, Eric Zudak, Ori Elkayam, Joseph F Merola, Jeffrey Chau, Mitsumasa Kishimoto, Victoria Furer, and Philip S Helliwell
Psoriatic arthritis., Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, Laura C Coates, Arthur Kavanaugh, William Tillett, Ying Ying Leung, Maarten deWit, Jose U Scher, and Philip J Mease
Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting., Dafna D Gladman, Philip S Helliwell, Denis Poddubnyy, and Philip Mease
Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting., Dafna D Gladman, Philip S Helliwell, Denis Poddubnyy, and Philip J Mease
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials., Alan J Kivitz, Oliver FitzGerald, Peter Nash, Shirley Pang, Valderilio F Azevedo, Cunshan Wang, and Liza Takiya
Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations., Bethea A Kleykamp, Robert H Dworkin, Dennis C Turk, Zubin Bhagwagar, Penney Cowan, Christopher Eccleston, Susan S Ellenberg, Scott R Evans, John T Farrar, Roy L Freeman, Louis P Garrison, Jennifer S Gewandter, Veeraindar Goli, Smriti Iyengar, Alejandro R Jadad, Mark P Jensen, Roderick Junor, Nathaniel P Katz, J Patrick Kesslak, Ernest A Kopecky, Dmitri Lissin, John D Markman, Michael P McDermott, Philip Mease, Alec B O'Connor, Kushang V Patel, Srinivasa N Raja, Michael C Rowbotham, Cristina Sampaio, Jasvinder A Singh, Ilona Steigerwald, Vibeke Strand, Leslie A Tive, Jeffrey Tobias, Ajay D Wasan, and Hilary D Wilson
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up., M Lebwohl, A Deodhar, C E M Griffiths, M A Menter, D Poddubnyy, W Bao, V Jehl, K Marfo, P Primatesta, A Shete, V Trivedi, and P J Mease
OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF., Ying-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, Richard Holland, Ashish J Mathew, Niti Goel, Jeffrey Chau, William Tillett, Christine Lindsay, Alexis Ogdie, Laura C Coates, Dafna D Gladman, Robin Christensen, Philip Mease, and Vibeke Strand
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group., Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J Mathew, Christine A Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C Coates, Philip J Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin, and Dafna D Gladman
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group., Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J Mathew, Christine A Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C Coates, Philip Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin, and Dafna D Gladman
Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis., Ying Ying Leung, William Tillett, Pil Hojgaard, Ana-Maria Orbai, Richard Holland, Ashish J Mathew, Niti Goel, Jeffrey Chau, Chris Lindsay, Alexis Ogdie, Laura C Coates, Robin Christensen, Philip Mease, Vibeke Strand, and Dafna D Gladman
Pain in Axial Spondyloarthritis: More to It Than Just Inflammation., Marina N Magrey and Philip J Mease
Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies., Dennis McGonagle, Iain B McInnes, Atul Deodhar, Georg Schett, May Shawi, Shelly Kafka, Chetan S Karyekar, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Christopher T Ritchlin, Proton Rahman, and Philip J Mease
Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis., Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Désirée van der Heijde, and Philip Mease
Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review., Philip Mease, Mohit Kumar Bhutani, Steven Hass, Esther Yi, Peter Hur, and Nina Kim
GRAPPA 2020 Update From the Education Committee., Philip Mease, Amit Garg, Philip S Helliwell, and GRAPPA Education Committee
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials., Philip Mease, Dafna D Gladman, Arthur Kavanaugh, Dennis McGonagle, Peter Nash, Benoit Guerette, Priscila Nakasato, Michele Brunori, Lichen Teng, and Iain B McInnes
Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy., Philip J Mease
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting., Philip J Mease, Leonard H Calabrese, Kristina Callis Duffin, Rebecca H Haberman, Rodrigo Firmino, Jose U Scher, Lori Schick, Kevin Winthrop, and Joseph F Merola
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting., Philip J Mease, Leonard H Calabrese, Kristina Callis Duffin, Rebecca H Haberman, Rodrigo Firmino, Jose U Scher, Lori Schick, Kevin Winthrop, and Joseph F Merola
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting., Philip J Mease, Leonard H Calabrese, Kristina Callis Duffin, Rebecca H Haberman, Rodrigo Firmino, Jose U Scher, Lori Schick, Kevin Winthrop, and Joseph F Merola
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study., Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, and Alice Gottlieb
GRAPPA 2020 Update From the Education Committee., Philip J Mease, Amit Garg, Philip S Helliwell, and Philip S. Helliwell on behalf of the GRAPPA Education Committee
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study., Philip J Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Aimee Readie, Shephard Mpofu, Eumorphia Maria Delicha, Luminita Pricop, and Desirée van der Heijde
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study., Philip J Mease, Apinya Lertratanakul, Kim A Papp, Filip E van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro W Keiserman, Xianwei Bu, Liang Chen, Reva M McCaskill, Patrick Zueger, Erin L McDearmon-Blondell, Aileen L Pangan, and William Tillett
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis., Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair, Wolf-Henning Boehncke, and Christopher Ritchlin
Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Robert R McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park, and Alexis Ogdie
Dr. Mease et al reply., Philip Mease, Robert R McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park, and Alexis Ogdie
Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry., Philip Mease, Scott Stryker, Mei Liu, Bob Salim, Sabrina Rebello, Mahdi Gharaibeh, and David H Collier
IL-23 and axial disease: do they come together?, Philip Mease and Filip van den Bosch
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study., Peter Nash, Philip Mease, Bruce Kirkham, Atul Singhal, Erhard Quebe-Fehling, Luminita Pricop, and Corine Gaillez
The ASAS-OMERACT core domain set for axial spondyloarthritis., V Navarro-Compán, A Boel, A Boonen, Philip Mease, R Landewé, U Kiltz, M Dougados, X Baraliakos, W Bautista-Molano, H Carlier, P Chiowchanwisawakit, H Dagfinrud, N de Peyrecave, B El-Zorkany, L Fallon, K Gaffney, M Garrido-Cumbrera, L S Gensler, N Haroon, Y H Kwan, P M Machado, W P Maksymowych, D Poddubnyy, M Protopopov, S Ramiro, B Shea, I H Song, S van Weely, and D van der Heijde
Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitas' PsA/Spondyloarthritis Registry., Alexis Ogdie, Taylor Blachley, Paul R Lakin, Blessing Dube, Robert R McLean, Peter Hur, and Philip Mease
Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group., Melissa Oliver, Aruni Jayatilleke, Eveline Wu, Farzana Nuruzzaman, Cassyanne Aguiar, Aleksander Lenert, Micol Romano, Gabriele Simonini, Samir Shah, Matthew Hollander, Alhanouf Alsaleem, Emily Fox, Alexander Theos, Athimalaipet V Ramanan, Anja Schnabel, Sivia Lapidus, Lori Tucker, Karen Onel, Seza Ozen, Fatma Dedeoglu, Polly J Ferguson, Beverley Shea, Jonathan Akikusa, Christian Hedrich, Philip Mease, and Yongdong Zhao
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies., Ana-Maria Orbai, M Elaine Husni, Dafna D Gladman, Ying Ying Leung, Stefan Siebert, William Tillett, Marijn Vis, Olivier Chambenoit, Xiangyi Meng, and Philip J Mease
Biopsychosocial rehabilitation for inflammatory arthritis and osteoarthritis: A systematic review and meta-analysis of randomized trials., Morten B Pedersen, Peter Thinggaard, Rinie Geenen, Marianne U Rasmussen, Maarten De Wit, Lyn March, Philip Mease, Ernest Choy, Philip G Conaghan, Lee Simon, Anne Faber Hansen, Simon Tarp, Berit Schiøttz-Christensen, Carsten B Juhl, Sabrina M Nielsen, Kirstine Amris, and Robin Christensen
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study., Lourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, Cheryl F Rosen, Christopher Ritchlin, Lihi Eder, Philip Mease, Soumya Reddy, Alexis Ogdie, Joseph F Merola, and Jose U Scher
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting., Lourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, April W Armstrong, Lihi Eder, Philip J Mease, Alexis Ogdie, Vibeke Strand, and Joseph F Merola
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting., Lourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, April W Armstrong, Lihi Eder, Philip J Mease, Alexis Ogdie, Vibeke Strand, and Joseph F Merola
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)., Denis Poddubnyy, Xenofon Baraliakos, Filip Van den Bosch, Jürgen Braun, Laura C Coates, Vinod Chandran, Torsten Diekhoff, Floris A van Gaalen, Lianne S Gensler, Niti Goel, Alice B Gottlieb, Désirée van der Heijde, Philip S Helliwell, Kay Geert A Hermann, Deepak Jadon, Robert G Lambert, Walter P Maksymowych, Philip Mease, Peter Nash, Fabian Proft, Mikhail Protopopov, Joachim Sieper, Murat Torgutalp, and Dafna D Gladman
Axial involvement in psoriatic arthritis: An update for rheumatologists., Denis Poddubnyy, Deepak R Jadon, Filip Van den Bosch, Philip J Mease, and Dafna D Gladman
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis., Proton Rahman, Philip J Mease, Philip S Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P Kollmeier, Elizabeth C Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S Karyekar, and Chenglong Han
Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis., Proton Rahman, Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Philip J Mease, Alice B Gottlieb, Shelly Kafka, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang, and Iain B McInnes
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study., Marie Skougaard, Tanja S Jørgensen, Mia J Jensen, Christine Ballegaard, Jørgen Guldberg-Møller, Alexander Egeberg, Robin Christensen, Peter Benzin, Zara R Stisen, Joseph F Merola, Laura C Coates, Vibeke Strand, Philip Mease, and Lars Erik Kristensen
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting., Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Philip J Mease, Alexis Ogdie, Denis O'Sullivan, Stephen R Pennington, Thorvardur Löve, Alberto Cauli, Leonieke van Mens, Robin Waxman, Jose U Scher, Anne Barton, Christopher T Ritchlin, and Oliver FitzGerald
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting., Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Philip Mease, Alexis Ogdie, Denis O'Sullivan, Stephen R Pennington, Thorvardur Löve, Alberto Cauli, Leonieke van Mens, Robin Waxman, Jose U Scher, Anne Barton, Christopher T Ritchlin, and Oliver FitzGerald
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination., Vibeke Strand, Philip Mease, Ervant J Maksabedian Hernandez, Bradley S Stolshek, Lyrica X H Liu, David H Collier, Gregory Kricorian, and Joseph F Merola
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1., Vibeke Strand, Philip Mease, Enrique R Soriano, Mitsumasa Kishimoto, Carlo Salvarani, Christopher D Saffore, Patrick Zueger, Erin McDearmon-Blondell, Koji Kato, and Dafna D Gladman
Familial cold autoinflammatory syndrome with rheumatoid arthritis., Brooke Walterscheid, Jeannie Nguyen, Swetha Gadwala, Goutam Shome, Michelle Tarbox, and James A Tarbox
Submissions from 2020
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews., Rikke A Andreasen, Lars E Kristensen, Xenofon Baraliakos, Vibeke Strand, Philip Mease, Maarten de Wit, Torkell Ellingsen, Inger Marie J Hansen, Jamie Kirkham, George A Wells, Peter Tugwell, Lara Maxwell, Maarten Boers, Kenneth Egstrup, and Robin Christensen
Performance and Predictors of Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated With Adalimumab., Laura C Coates, Sonya Abraham, William Tillett, Philip Mease, Sofia Ramiro, Tianshuang Wu, Xin Wang, Aileen L Pangan, and In-Ho Song
Methotrexate in Psoriasis and Psoriatic Arthritis., Laura C Coates, Joseph F Merola, Suzanne M Grieb, Philip Mease, and Kristina Callis Duffin
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis., Laura C Coates, Joseph F Merola, Philip Mease, Alexis Ogdie, Dafna D Gladman, Vibeke Strand, Leonieke J J van Mens, Lyrica Liu, Priscilla K Yen, David H Collier, Gregory Kricorian, James B Chung, and Philip S Helliwell
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study., Laura C Coates, Peter Nash, Tore K Kvien, Laure Gossec, Philip Mease, Lawrence Rasouliyan, Luminita Pricop, Steffen M Jugl, Kunal K Gandhi, Corine Gaillez, and Josef S Smolen
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial., Atul Deodhar, Philip Mease, Proton Rahman, Victoria Navarro-Compán, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Luis Leon, Mingyang Shan, Ann Leung, Kurt De Vlam, and Vibeke Strand
GRAPPA 2019 Project Report., Niti Goel, Laura C Coates, Gabriele De Marco, Lihi Eder, Oliver FitzGerald, Philip S Helliwell, Ying Ying Leung, Walter P Maksymowych, Philip Mease, Mikkel Østergaard, Denis O'Sullivan, Denis Poddubnyy, Christopher T Ritchlin, and Dafna D Gladman
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials., Alice B Gottlieb, Philip Mease, Bruce Kirkham, Peter Nash, Alejandro C Balsa, Bernard Combe, Jürgen Rech, Xuan Zhu, David James, Ruvie Martin, Gregory Ligozio, Ken Abrams, and Luminita Pricop
Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study., Tanja Schjødt Jørgensen, Marie Skougaard, Rebekka Lund Hansen, Christine Ballegaard, Philip Mease, Vibeke Strand, Lene Dreyer, and Lars Erik Kristensen
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review., Ying-Ying Leung, Richard Holland, Ashish J Mathew, Christine Lindsay, Niti Goel, Alexis Ogdie, Ana-Maria Orbai, Pil Hojgaard, Jeffrey Chau, Laura C Coates, Vibeke Strand, Dafna D Gladman, Robin Christensen, William Tillett, and Philip Mease
Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis., Ying Ying Leung, Ana-Maria Orbai, Alexis Ogdie, Pil Hojgaard, Richard Holland, Niti Goel, Jeffrey Chau, Laura C Coates, Vibeke Strand, Dafna D Gladman, Philip Mease, Robin Christensen, and William Tillett
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates., Ying Ying Leung, William Tillett, Ana-Maria Orbai, Alexis Ogdie, Lihi Eder, Laura C Coates, Richard Holland, Anna Antony, Niti Goel, Philip Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Christine A Lindsay, Kristina Callis Duffin, and Dafna D Gladman
Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis., Sara C Martinez, Mohamed Mohamed, Jessica Potts, Abhishek Abhishek, Edward Roddy, Michael Savage, Aditya Bharadwaj, Chun Shing Kwok, Rodrigo Bagur, and Mamas A Mamas
Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis., Sara C Martinez, Mohamed Mohamed, Jessica Potts, Abhishek Abhishek, Edward Roddy, Michael Savage, Aditya Bharadwaj, Chun Shing Kwok, Rodrigo Bagur, and Mamas A Mamas
